Literature DB >> 17894941

Evaluation of candidate methylation markers to detect cervical neoplasia.

Narayan Shivapurkar1, Mark E Sherman, Victor Stastny, Chinyere Echebiri, Janet S Rader, Ritu Nayar, Thomas A Bonfiglio, Adi F Gazdar, Sophia S Wang.   

Abstract

OBJECTIVE: Studies of cervical cancer and its immediate precursor, cervical intraepithelial neoplasia 3 (CIN3), have identified genes that often show aberrant DNA methylation and therefore represent candidate early detection markers. We used quantitative PCR assays to evaluate methylation in five candidate genes (TNFRSF10C, DAPK1, SOCS3, HS3ST2 and CDH1) previously demonstrated as methylated in cervical cancer.
METHODS: In this analysis, we performed methylation assays for the five candidate genes in 45 invasive cervical cancers, 12 histologically normal cervical specimens, and 23 liquid-based cervical cytology specimens confirmed by expert review as unequivocal demonstrating cytologic high-grade squamous intraepithelial lesions, thus representing the counterparts of histologic CIN3.
RESULTS: We found hypermethylation of HS3ST2 in 93% of cancer tissues and 70% of cytology specimens interpreted as CIN3; hypermethylation of CDH1 was found in 89% of cancers and 26% of CIN3 cytology specimens. Methylation of either HS3ST2 or CDH1 was observed in 100% of cervical cancer tissues and 83% of CIN3 cytology specimens. None of the five genes showed detectable methylation in normal cervical tissues.
CONCLUSION: Our data support further evaluation of HS3ST2 and CDH1 methylation as potential markers of cervical cancer and its precursor lesions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17894941      PMCID: PMC2718832          DOI: 10.1016/j.ygyno.2007.08.057

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  28 in total

Review 1.  Targeting death and decoy receptors of the tumour-necrosis factor superfamily.

Authors:  Avi Ashkenazi
Journal:  Nat Rev Cancer       Date:  2002-06       Impact factor: 60.716

2.  Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix.

Authors:  S M Dong; H S Kim; S H Rha; D Sidransky
Journal:  Clin Cancer Res       Date:  2001-07       Impact factor: 12.531

3.  Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130.

Authors:  S E Nicholson; D De Souza; L J Fabri; J Corbin; T A Willson; J G Zhang; A Silva; M Asimakis; A Farley; A D Nash; D Metcalf; D J Hilton; N A Nicola; M Baca
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 4.  The power and the promise of DNA methylation markers.

Authors:  Peter W Laird
Journal:  Nat Rev Cancer       Date:  2003-04       Impact factor: 60.716

5.  Aberrant methylation during cervical carcinogenesis.

Authors:  A K Virmani; C Muller; A Rathi; S Zoechbauer-Mueller; M Mathis; A F Gazdar
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

Review 6.  The DAP kinase family of pro-apoptotic proteins: novel players in the apoptotic game.

Authors:  D Kögel; J H Prehn; K H Scheidtmann
Journal:  Bioessays       Date:  2001-04       Impact factor: 4.345

7.  Estimates of the world-wide prevalence of cancer for 25 sites in the adult population.

Authors:  Paola Pisani; Freddie Bray; D Maxwell Parkin
Journal:  Int J Cancer       Date:  2002-01-01       Impact factor: 7.396

8.  Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.

Authors:  Shalini L Kulasingam; James P Hughes; Nancy B Kiviat; Constance Mao; Noel S Weiss; Jane M Kuypers; Laura A Koutsky
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

9.  Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers.

Authors:  Kazuaki Miyamoto; Kiyoshi Asada; Takashi Fukutomi; Eriko Okochi; Yukiko Yagi; Tadashi Hasegawa; Toshimasa Asahara; Takashi Sugimura; Toshikazu Ushijima
Journal:  Oncogene       Date:  2003-01-16       Impact factor: 9.867

10.  High-risk HPV type-specific clearance rates in cervical screening.

Authors:  N W J Bulkmans; J Berkhof; S Bulk; M C G Bleeker; F J van Kemenade; L Rozendaal; P J F Snijders; C J L M Meijer
Journal:  Br J Cancer       Date:  2007-03-06       Impact factor: 7.640

View more
  20 in total

1.  Novel epigenetic changes in CDKN2A are associated with progression of cervical intraepithelial neoplasia.

Authors:  N Ari Wijetunga; Thomas J Belbin; Robert D Burk; Kathleen Whitney; Maria Abadi; John M Greally; Mark H Einstein; Nicolas F Schlecht
Journal:  Gynecol Oncol       Date:  2016-07-09       Impact factor: 5.482

Review 2.  Epigenetics and cervical cancer: from pathogenesis to therapy.

Authors:  Jinchuan Fang; Hai Zhang; Sufang Jin
Journal:  Tumour Biol       Date:  2014-02-20

Review 3.  Potential role of cancer stem cells as biomarkers and therapeutic targets in cervical cancer.

Authors:  Niyati Sudhalkar; Nidul P Rathod; Ashwathi Mathews; Supriya Chopra; Harshini Sriram; Shyam K Shrivastava; Jayant S Goda
Journal:  Cancer Rep (Hoboken)       Date:  2018-11-08

4.  Increased methylation of human papillomavirus type 16 DNA is associated with the severity of cervical lesions in infected females from northeast China.

Authors:  Wei Wang; Zhengrong Sun; Jianhua Liu; Guili Wang; Zhitao Lu; Weiqiang Zhou; Te Qi; Qiang Ruan
Journal:  Oncol Lett       Date:  2017-03-24       Impact factor: 2.967

5.  Quantitative assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens.

Authors:  Jo-Heon Kim; Yoo Duk Choi; Ji Shin Lee; Jae Hyuk Lee; Jong Hee Nam; Chan Choi; Sun-Seog Kweon; Mary Jo Fackler; Saraswati Sukumar
Journal:  Virchows Arch       Date:  2010-05-23       Impact factor: 4.064

Review 6.  Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science.

Authors:  Nicolas Wentzensen; Mark E Sherman; Mark Schiffman; Sophia S Wang
Journal:  Gynecol Oncol       Date:  2008-12-02       Impact factor: 5.482

Review 7.  Heparan sulfate 3-O-sulfation: a rare modification in search of a function.

Authors:  Bryan E Thacker; Ding Xu; Roger Lawrence; Jeffrey D Esko
Journal:  Matrix Biol       Date:  2013-12-19       Impact factor: 11.583

8.  Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study.

Authors:  Erin M Siegel; Steven Eschrich; Kathryn Winter; Bridget Riggs; Anders Berglund; Abidemi Ajidahun; Jeff Simko; Jennifer Moughan; Jaffer Ajani; Anthony Magliocco; Abul Elahi; Sarah Hoffe; David Shibata
Journal:  Dis Colon Rectum       Date:  2014-08       Impact factor: 4.585

9.  Discovery and validation of methylation markers for endometrial cancer.

Authors:  Nicolas Wentzensen; Jamie N Bakkum-Gamez; J Keith Killian; Joshua Sampson; Richard Guido; Andrew Glass; Lisa Adams; Patricia Luhn; Louise A Brinton; Brenda Rush; Lori d'Ambrosio; Munira Gunja; Hannah P Yang; Montserrat Garcia-Closas; James V Lacey; Jolanta Lissowska; Karl Podratz; Paul Meltzer; Viji Shridhar; Mark E Sherman
Journal:  Int J Cancer       Date:  2014-03-31       Impact factor: 7.396

10.  Genome-wide methylation profiling reveals Zinc finger protein 516 (ZNF516) and FK-506-binding protein 6 (FKBP6) promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population.

Authors:  Priscilla Brebi; Leonel Maldonado; Maartje G Noordhuis; Carmen Ili; Pamela Leal; Patricia Garcia; Mariana Brait; Judit Ribas; Christina Michailidi; Jimena Perez; Ethan Soudry; Oscar Tapia; Pablo Guzman; Sergio Muñoz; Leander Van Neste; Wim Van Criekinge; Rafael Irizarry; David Sidransky; Juan C Roa; Rafael Guerrero-Preston
Journal:  Epigenetics       Date:  2013-11-15       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.